Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects identifier:
NCT03012321 (


Study Contact Information:

 For more information, contact the study coordinator by phone (312)695-1301 or email.

About the Study

This is a phase II study looking at different treatment combinations for men with metastatic, castration resistant prostate cancer (mCRPC) to see which is most effective for improving progression free survival (keeping the cancer from progressing). The study will include testing for genes within the tumor to determine eligibility for the study. 

The study multiple treatment arms. Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations or defects will be randomly assigned to one of the treatment arms of the study. Patients with tumors that have mutations in other DNA repair genes including FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A will be assigned to Arm IV with single agent olaparib.

Type of Study

This is a randomized, open-label, 4-arm study. This study allows crossover. 

What the Study Entails

Study Sites

Principal Investigator

Maha Hussain at Northwestern University: 312-695-6180 

This Study is Open To:

NOTE: This study is now closed. 


This Study is Not Open To:

NOTE: This study is now closed. 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.